In the last trading session, 8.61 million shares of the ImmunityBio Inc (NASDAQ:IBRX) were traded, and its beta was 0.71. Most recently the company’s share price was $2.85, and it changed around -$0.44 or -13.37% from the last close, which brings the market valuation of the company to $2.08B. IBRX currently trades at a discount to its 52-week high of $10.53, offering almost -269.47% off that amount. The share price’s 52-week low was $2.28, which indicates that the current value has risen by an impressive 20.0% since then.
ImmunityBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended IBRX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. ImmunityBio Inc is expected to report earnings per share of -0.15 for the current quarter.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX has showed a red trend with a performance of -13.37% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.51 on recent trading dayincreased the stock’s daily price by 18.8%. The company’s shares are currently up 11.33% year-to-date, but still down -11.49% over the last five days. On the other hand, ImmunityBio Inc (NASDAQ:IBRX) is -17.87% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 52.5% from its current value. Analyst projections state that IBRX is forecast to be at a low of $6 and a high of $6.
ImmunityBio Inc (IBRX) estimates and forecasts
The year-over-year growth rate is expected to be 612.96%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 15.43M in revenue for the current quarter. 2 analysts expect ImmunityBio Inc to make 19.83M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 40k and 1.05M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 38,463.75%. Forecasts for the next quarter put sales growth at 1,794.13%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.17%.
IBRX Dividends
ImmunityBio Inc’s next quarterly earnings report is expected to be released in April.
BLACKROCK INC., with 1.6978% or 11.42 million shares worth $72.19 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
